Astrana Health, Inc.

---

source: coverage-next-full step: 01 title: Business Overview ticker: ASTH company: Astrana Health, Inc. date: 2026-06-17

Step 01 — Business Overview: Astrana Health (ASTH)

1. Business Summary

Astrana Health, Inc. (ASTH) is a physician-centric, technology-powered, risk-bearing healthcare management company headquartered in Alhambra, California. [S1] Founded in the early 1990s as an Independent Physician Association (IPA) manager operating primarily in Southern California's densely insured Medicare Advantage market, the company rebranded from APA/Apollo Medical Holdings to Astrana Health in 2023 to signal a broader national platform ambition.

Astrana's core value proposition is converting independent physicians from fee-for-service (FFS) billing into full-risk, capitated arrangements where they accept a monthly premium per patient from a health plan and absorb total medical cost risk. The company provides the data infrastructure, care management protocols, managed services organization (MSO) capabilities, and capital necessary to make this transition economically viable for physician groups at a range of sophistication levels.

Following the July 2025 acquisition of certain assets of Prospect Medical Holdings for ~$707M in DDTL financing, Astrana has become the largest independent (non-payer-owned) physician-centric VBC organization in the US by revenue, with ~$3.18B in FY2025 revenue and ~1.6 million patients under management across California, Texas, Arizona, Nevada, and Rhode Island. [S1, S2]

2. Three-Segment Business Model

2A. Care Partners (~95% of FY2025 Revenue = $3.02B)

The core economic engine. Care Partners builds and manages a network of Risk-Bearing Organizations (RBOs): IPAs, ACOs, and Restricted Knox-Keene (RKK) health plans. [S2]

How it works:

1. A health plan (e.g., Anthem, Humana, L.A. Care) contracts with an RBO on a capitated (PMPM) basis — paying a fixed monthly amount per enrolled member regardless of services used
2. The RBO (managed by Astrana) then sub-delegates risk to physicians, who earn more when medical costs are controlled
3. Astrana earns revenue from the capitation flow and retains a management fee / spread; it also assumes varying layers of financial risk (professional risk, institutional risk, or full risk) depending on the product structure

Risk-bearing structures (in order of risk taken):

• Professional-risk IPA: Takes only physician/outpatient risk; hospital/institutional costs remain with the payer
• Full-risk IPA: Takes all medical costs including hospital; higher premium but requires robust utilization management
• RKK Plan: California Restricted Knox-Keene license allows Astrana's subsidiaries to function as a mini-health plan, assuming both professional and institutional risk directly from CMS or a payer — highest risk and highest potential spread per member

Strategic shift: Full-risk capitated arrangements grew from 0% of capitation revenue in 2021 to 80% in Q1 2026 — a deliberate strategic migration toward higher-risk, higher-reward contracts. [S5]

Scale (Dec 31, 2025): 28 RBOs managed; ~1.6M patients; 20,000+ contracted physicians. [S2]

2B. Care Enablement (~8% of FY2025 Revenue = $247M)

A technology and managed-services platform that Astrana deploys for independent physician groups, IPAs, and medical groups that are not yet ready to join its own risk-bearing network. [S2]

Services provided:

• Population health management (PHM) software and analytics
• Utilization management and prior authorization
• Claims processing and RCM
• Credentialing, quality reporting, and payer contracting
• Physician recruiting and care gap closure

Revenue model: Management fee income (typically fixed or per-member basis) from the 28 independently managed IPAs/groups as of Dec 31, 2025 (vs. 20 at YE2024). The Prospect MSO added 8 groups.

Strategic rationale: Care Enablement is a funnel that converts technology customers into organic acquisition targets. By managing a physician group's operations before acquisition, Astrana reduces integration risk and physician attrition when it eventually buys the group or converts it into its own RBO network. [S3]

Technology differentiation (disclosed in FY2025 investor presentation):

• 67% prior authorization automation rate
• 24% higher care gap closure rates vs. non-Astrana-managed groups
• AI-assisted population health management tools [S3]

2C. Care Delivery (~8% of FY2025 Revenue = $251M)

Direct patient care operations across 60+ clinic locations. [S2]

Service lines:

• Primary care clinics (including post-acute/skilled nursing)
• Specialty care: cardiology, endocrinology, ophthalmology
• Hospitalist/intensivist services
• Urgent care
• Outpatient imaging and ambulatory surgery centers (ASCs)
• Laboratory services
• Specialty pharmacy (RightRx, added via Prospect)
• Acute care hospital: Foothill Regional Medical Center (FRMC), added via Prospect

Role in the system: Care Delivery clinics both generate direct revenue and route patients into Astrana's IPA/RBO care management system, optimizing panel utilization and quality metrics. The hospital (FRMC) is strategically significant because it allows Astrana to manage high-cost institutional risk without depending on third-party hospital systems.

Operating note: Care Delivery posted a slight operating loss ($-2.0M) in FY2025, primarily due to Prospect integration costs and legacy operational challenges at the acquired hospital and specialty clinics. [S2]

3. Value Chain Layer Map

PAYERS (Medicare Advantage plans, Medicaid MCOs, Commercial HMOs)
    │
    │  Capitation PMPM
    ▼
CARE PARTNERS SEGMENT (Astrana-managed RBOs / IPAs / RKK Plans)
    │  Sub-delegated capitation + risk management
    ├──►  CARE ENABLEMENT (MSO services, population health tech, utilization mgmt)
    │              Manages 28 external groups; feeds pipeline for M&A / RBO conversion
    │
    ▼
CONTRACTED PHYSICIAN NETWORK (20,000+ physicians, 28 RBOs)
    │  Referrals, care management protocols
    ▼
CARE DELIVERY (60+ clinics, 1 hospital, pharmacy)
    └──►  Direct patient care → quality metrics → cost management → better MCR

The flywheel: Lower medical cost ratio → Better risk-pool settlements → More capital for physician recruitment → Larger network → Better payer contracting leverage → Lower PMPM cost per member.

4. Revenue Architecture Summary

Revenue Stream	FY2025	% of Total	Nature
Capitation, net	$2,924M	91.9%	Risk-bearing, MCR-sensitive
Risk pool settlements & incentives	$86M	2.7%	Performance bonuses from payers
Fee-for-service (net)	$113M	3.5%	Non-risk, volume-based
Management fee income	$30M	1.0%	Recurring, low-risk (Care Enablement)
Other revenue	$28M	0.9%	Pharmacy, ancillary
Total	$3,182M	100%

5. Key Customers and Payer Relationships

Astrana's customers are health plans that pay the capitation. In Southern California's Medicare Advantage market, the major payers are:

• L.A. Care Health Plan (one of the nation's largest Medicaid/Medicare plans)
• Anthem Blue Cross (California)
• Humana
• Aetna (CVS)
• Multiple Medi-Cal managed care plans (California Medicaid)

Concentration risk: The majority of revenue is concentrated in California's MA/Medi-Cal market. The Prospect acquisition added diversification into Texas, Arizona, and Rhode Island but California likely remains >60% of revenue. No single payer is publicly disclosed as >10% of revenue. [S2]

6. Business Model Strengths and Vulnerabilities

Strengths:

• 35-year IPA management heritage in Southern California = deep payer relationships and operational know-how
• Proprietary tech platform creates switching costs for physician groups
• Full-risk model captures more value per member as medical costs are managed below the capitation rate
• Care Enablement → Care Partners funnel creates organic M&A sourcing and lower integration risk
• PMPM capitation revenue is largely recurring and less cyclical than FFS volumes

Vulnerabilities:

• Medical Cost Ratio is the key risk: adverse coding, flu seasons, or high-cost members can turn profitable capitation into losses rapidly
• California HMO/IPA market is mature and competitive — organic member growth requires market share gains or payer contract expansion
• Post-Prospect leverage ($700M net debt) limits financial flexibility for additional acquisitions or covenant-stress scenarios
• Material weakness in internal controls (acquisition accounting) is an execution/credibility risk

Source Index

[S1] ASTH XBRL Data + Filing Inventory (retrieved 2026-06-17) [S2] ASTH 10-K FY2025: Business Description, Segment Data (filed 2026-03-12) [S3] Astrana Health Investor Presentation (FY2025 / 2026 Guidance) [S4] ASTH 10-K FY2024 (filed 2025-03) [S5] Consensus data & earnings release Q1 2026 (retrieved 2026-06-17)

---

source: coverage-next-full step: 04 title: Financial Quality & Adversarial Sweep ticker: ASTH company: Astrana Health, Inc. date: 2026-06-17

Step 04 — Financial Quality & Adversarial Sweep: Astrana Health (ASTH)

1. Financial Statement Quality

Key Statement Adjustments

a) GAAP vs. Non-GAAP Divergence (significant)

Metric	FY2025 GAAP	FY2025 Non-GAAP	Delta	Source
Net income (total)	$24,076K	$108,581K	+$84,505K	SBC + M&A + D&A addbacks
EPS (diluted, attributed to ASTH)	$0.46	$2.20	+$1.74	Adj. net income / shares
EBITDA	$123,126K	$205,424K	+$82,298K	Adj. items below

Primary non-GAAP adjustments in FY2025:

• SBC: $38,601K — significant relative to GAAP net income of $24M; exceeds GAAP earnings by 60%+
• Transaction/integration costs (Prospect): $25,862K
• Legal matter (CFC HP arbitration): $13,000K
• Debt issuance/refinancing costs
• D&A (primarily intangible amortization from acquisitions): $45,749K

Assessment: The GAAP vs. non-GAAP gap is widening as M&A activity intensifies. SBC alone exceeding GAAP net income is a quality concern, though common in healthcare management companies. Intangible amortization from Prospect ($17.3M in H2 2025) is real economic cost given goodwill/intangible risk but management argues it's non-cash.

b) Goodwill Quality

FY	Goodwill ($000s)	Total Assets	Goodwill as % of Assets
FY2023	$163,093	$920,052	17.7%
FY2024	$419,253	$1,354,894	30.9%
FY2025	$865,305	$2,218,661	39.0%

Goodwill nearly doubled in FY2025 from Prospect (acquired at ~$865M gross goodwill). This represents ~39% of total assets — elevated but within range for a serial acquiror in physician management. The risk: if Prospect underperforms financially, impairment charges could be material. Given the material weakness in acquisition accounting noted in the FY2025 10-K, there is some uncertainty about the precise purchase price allocation. [S2]

c) Revenue Recognition Quality

Capitation revenue is recognized ratably over the contract period (monthly PMPM). Risk pool settlements are recognized when determined (i.e., when payer performance periods close), which introduces timing variability. Management fee income is recognized as services are provided. No revenue concerns identified — these are straightforward methods appropriate to the industry.

d) Minority Non-Controlling Interests

The company consolidates numerous IPAs, RBOs, and VIEs through voting rights or economic arrangements. Minority interest (NCI) net income of $1.6M in FY2025 is small relative to the full enterprise but the NCI balance sheet amount warrants monitoring. IPA partners with minority stakes could create valuation complexity if buy-out provisions are triggered. [S2]

Financial Quality Score: MEDIUM

Rationale: Strong cash conversion (FCF > GAAP earnings), contractual revenue, and improving FCF trend are positive. Weakened by: high GAAP-vs-non-GAAP gap (SBC dominates), elevated goodwill after rapid M&A, material weakness in acquisition accounting, and MCR compression.

2. Balance Sheet Stress Analysis

Debt Covenant Analysis

Credit Agreement (as of Feb 2025 — Second Amended and Restated):

• $300M Revolving Credit Facility (5-year, matures Feb 2030)
• $250M Term Loan A (5-year, matures Feb 2030)
• $745M Delayed Draw Term Loan A (drawn $707.3M for Prospect)
• Total drawn: $1,052M

Financial covenants (typical for this structure — not explicitly disclosed in 10-K excerpts reviewed):

• Maximum Net Total Leverage Ratio: likely ≤5.0x (standard for leveraged healthcare deals)
• At Dec 31, 2025: Net Leverage = (~$1,052M gross debt - $429M cash) / $205M Adj. EBITDA ≈ 3.0x — comfortable

Interest rate risk: Term loans at floating rate (SOFR + spread); $200M hedged with interest rate swap at 3.179% fixed. Remaining ~$800M+ at variable rate. A 100bp rise in rates → ~$8M incremental annual interest expense. At current SOFR (~4.3–5%), total interest runs ~$50–60M per year — already material relative to GAAP operating income of $78M. [S2]

Working Capital Dynamics

Item	Dec 31, 2025	Dec 31, 2024
Current assets	$863,313K	$638,496K
Current liabilities	$615,273K	$365,608K
Working capital	$248,040K	$272,888K

Working capital declined $25M despite revenue growth — primarily driven by the mix-in of Prospect's capitation-heavy operations (higher medical cost payables in current period). Claims payable timing is a normal feature of capitation businesses.

3. Adversarial Research Sweep

Known Controversies, Litigation, and Investigations

a) CFC HP Arbitration (Material Item) The FY2025 10-K discloses a $13.0M loss contingency recognized in Q3 2025 related to a legal matter described as "CFC HP" — likely a contracted payer or care-partner dispute involving care management obligations. The arbitration appears to be related to California Family Care / Health Plan contracting disputes. This was partially driving Q3 2025 operating income compression and was a one-time item per management.

b) Material Weakness in Internal Controls (Active Risk) As disclosed March 2, 2026 alongside Q4 2025 results:

• Material weakness in internal controls over financial reporting
• Specifically related to acquisition and purchase accounting processes for the Prospect acquisition
• Management stated no material misstatement and no restatements required
• The 10-K was filed late (Form 12b-25 extension)
• This is a genuine credibility risk until remediation is confirmed by auditors in FY2026 10-K

c) SEC/Regulatory Scrutiny (No Active Investigations Found) No evidence of SEC enforcement actions or DOJ/OIG investigations involving Astrana Health as of 2026. The VBC industry broadly faces CMS scrutiny for upcoding/improper risk adjustment, but no ASTH-specific action found.

d) Prior Entity History Astrana's predecessor entity (APA/Apollo Medical Holdings) was a smaller California IPA operator. No major legacy litigation identified from the prior entity that is material to current operations.

e) Prospect Medical Holdings Legacy Issues Prospect Medical Holdings, the company from which Astrana acquired assets, had a troubled history:

• Prospect faced significant financial distress, creditor disputes, and state regulatory issues prior to the ASTH acquisition
• ASTH specifically carved out certain liabilities (hence "Excluded Assets" structure)
• The acquisition structure was designed to ring-fence Prospect's legacy issues
• However, the operational integration complexity (hospital, multi-state medical groups, pharmacy) introduces execution risk that is hard to isolate from balance sheet risk

f) Short Seller / Bearish Research No major short-seller campaigns against ASTH identified. Short interest is modest (~3.9% of float) and declining. The main bear case is macro/operational (margin compression, leverage) rather than fraud allegations.

Financial Quality Red Flags

Flag	Severity	Disposition
SBC > GAAP net income	MEDIUM	Structural feature of growth healthcare companies; monitor for dilution
Goodwill = 39% of assets	MEDIUM	Acquisition-driven; impairment risk if Prospect underperforms
Material weakness (acquisition accounting)	MEDIUM-HIGH	Active; management says no restatement; monitor for FY2026
MCR rising (89.3% FY2025 vs 86.7% FY2024)	HIGH	Key operational risk; Prospect integration the primary driver
High leverage (~3x net debt/Adj.EBITDA)	MEDIUM	Within covenant; management targeting <2.5x in 12–18 months

4. Cash Flow Quality

Operating Cash Flow vs. Net Income Reconciliation

	FY2025	FY2024
Net income (total)	$24,076	$49,932
+ D&A	$45,749	$27,927
+ SBC	$38,601	$34,536
+ Working capital changes	~$6,171	~($60,197)
= Operating CF	$114,597	$52,198
Less CapEx	~($10,106)	~($8,031)
= Free Cash Flow	~$104,491	~$44,167

FCF quality: HIGH — FCF substantially exceeds GAAP net income, driven by non-cash SBC and D&A. CapEx is very low (~0.3% of revenue) — consistent with an asset-light managed care model. Operating CF improvement in FY2025 was partly timing-driven (claims payment lags post-Prospect close).

Source Index

[S1] ASTH XBRL summary (retrieved 2026-06-17) [S2] ASTH 10-K FY2025 — Balance sheet, MD&A, notes (filed 2026-03-12) [S3] StockAnalysis.com financial summary [S4] Consensus / analyst data (retrieved 2026-06-17) [S5] ASTH 10-K FY2024 — Comparison period data